In the last trading session, 1.25 million shares of the Autolus Therapeutics plc ADR (NASDAQ:AUTL) were traded, and its beta was 2.00. Most recently the company’s share price was $2.94, and it changed around $0.02 or 0.68% from the last close, which brings the market valuation of the company to $782.39M. AUTL currently trades at a discount to its 52-week high of $7.45, offering almost -153.4% off that amount. The share price’s 52-week low was $2.69, which indicates that the current value has risen by an impressive 8.5% since then. We note from Autolus Therapeutics plc ADR’s average daily trading volume that its 10-day average is 1.51 million shares, with the 3-month average coming to 1.51 million.
Autolus Therapeutics plc ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended AUTL as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Autolus Therapeutics plc ADR is expected to report earnings per share of -0.24 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Autolus Therapeutics plc ADR (NASDAQ:AUTL) trade information
Instantly AUTL has showed a green trend with a performance of 0.68% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.45 on recent trading dayincreased the stock’s daily price by 14.78%. The company’s shares are currently down -54.35% year-to-date, but still down -11.45% over the last five days. On the other hand, Autolus Therapeutics plc ADR (NASDAQ:AUTL) is -17.65% down in the 30-day period. We can see from the shorts that 6.25 million shares have been sold at a short interest cover period of 2.89 day(s).
The consensus price target as assigned by Wall Street analysts is $7.6, which translates to bulls needing to increase their stock price by 61.32% from its current value. Analyst projections state that AUTL is forecast to be at a low of $7.6 and a high of $7.6.
Autolus Therapeutics plc ADR (AUTL) estimates and forecasts
Autolus Therapeutics plc ADR share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -26.50 percent over the past six months and at a 21.67% annual growth rate that is well above the industry average of 17.10%. The year-over-year growth rate is expected to be 920.38%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 2.98M in revenue for the current quarter. 1 analysts expect Autolus Therapeutics plc ADR to make 17.52M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 73.59%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 3.32%.
AUTL Dividends
Autolus Therapeutics plc ADR’s next quarterly earnings report is expected to be released in January.
BLACKSTONE INC., with 9.2207% or 20.49 million shares worth $71.29 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Specialized-Health Care Fund and Fidelity Advisor Biotechnology Fund were the top two Mutual Funds as of Jul 31, 2024 . The former held 18.9 shares worth $55.55 million, making up 7.10% of all outstanding shares. On the other hand, Fidelity Advisor Biotechnology Fund held roughly 3.01 shares worth around $8.85 million, which represents about 1.13% of the total shares outstanding.
